Why IVDR matters for UK manufacturers in 2026
The EU In Vitro Diagnostic Regulation (IVDR, EU 2017/746) came into full force in May 2022, replacing the previous IVDD framework. Unlike its predecessor, IVDR reclassifies the vast majority of IVDs into higher-risk classes requiring notified body involvement — a significant shift that the UK diagnostics sector is still working through, compounded by the post-Brexit UKCA/CE-IVD dual compliance landscape.
For UK manufacturers exporting into European markets, compliance with IVDR is non-negotiable. And with UKCA marking deadlines having evolved several times since Brexit, the regulatory picture in 2026 requires careful navigation at both the technical and commercial level.
Under IVDR, Class D devices (highest risk — e.g. HIV, HCV, HBV tests) required notified body involvement from May 2022. Class C devices (e.g. most molecular infectious disease tests) were subject to transition deadlines extending to May 2025. By 2026, all manufacturers should have active IVDR conformity pathways or approved derogations in place.
The notified body bottleneck
One of the most significant operational challenges under IVDR has been the limited capacity of EU-designated notified bodies. As of early 2026, fewer than 20 notified bodies are fully designated under IVDR, creating substantial delays for manufacturers seeking conformity assessments — particularly for Class C and D devices with mandatory notified body review.
For UK manufacturers without an established EU notified body relationship, the backlog can extend timelines by 18–24 months. Companies that have not yet initiated a notified body engagement should treat this as a critical business risk — not a regulatory administrative task.
“The notified body capacity issue is not going away in 2026. Any manufacturer without a confirmed IVDR notified body engagement today is already behind schedule for any device requiring conformity assessment.” — Expert input from FutureDX 2026 speaker faculty.
UKCA and the UK domestic landscape
Within Great Britain, the UKCA marking requirement continues to evolve. The MHRA has extended recognition of CE marking for certain IVD categories while the UKCA framework is consolidated — but manufacturers should not assume indefinite equivalence. Regulatory divergence between UKCA and CE-IVD is a genuine medium-term risk for companies with pan-European product portfolios.
Northern Ireland continues to operate under EU IVDR under the Windsor Framework, creating additional complexity for UK manufacturers selling across the devolved nations.
- Confirm IVDR risk classification for all IVDs in your portfolio
- Engage an EU-designated IVDR notified body if not already in process
- Establish an EU Authorised Representative (EUAR) if you have no EU legal presence
- Review clinical evidence requirements under IVDR vs your existing IVDD documentation
- Update your Post-Market Surveillance (PMS) and Post-Market Performance Follow-Up (PMPF) plans
- Monitor MHRA guidance updates on UKCA timelines and CE recognition extensions
FutureDX 2026 — regulatory track
IVDR compliance, UKCA strategy, and the broader CE-IVD regulatory landscape will feature prominently in the Day 1 programme at FutureDX Summit 2026 in London on 9–10 September. We will be hosting dedicated regulatory sessions and a practitioner panel specifically for UK manufacturers navigating dual compliance.